{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:21:35Z","timestamp":1759159295210,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001427","name":"All India Council for Technical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001427","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s13346-023-01386-9","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T20:21:39Z","timestamp":1688502099000},"page":"116-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Enhanced tissue distribution of ritonavir-loaded nanostructured lipid carriers\u2014recommending its dose reduction"],"prefix":"10.1007","volume":"14","author":[{"given":"Srinivas Reddy","family":"Jitta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Salwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navya Ajitkumar","family":"Bhaskaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirleen Miriam","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri Pragnya","family":"Cheruku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanishree","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onkar Prakash","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","unstructured":"Moyle GJ, Gazzard BG, Cooper DA, Gatell J. Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs. 1998;55(3):383\u2013404. https:\/\/doi.org\/10.2165\/00003495-199855030-00005.","DOI":"10.2165\/00003495-199855030-00005"},{"key":"1386_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ejps.2018.01.026","volume":"115","author":"H Xu","year":"2018","unstructured":"Xu H, Krakow S, Shi Y, Rosenberg J, Gao P. In vitro characterization of ritonavir formulations and correlation to in vivo performance in dogs. Eur J Pharm Sci. 2018;115:286\u201395. https:\/\/doi.org\/10.1016\/j.ejps.2018.01.026.","journal-title":"Eur J Pharm Sci"},{"key":"1386_CR3","doi-asserted-by":"publisher","unstructured":"Mehta C, Narayan R, Aithal G, Pandiyan S, Bhat P, Dengale S, et al. Molecular simulation driven experiment for formulation of fixed dose combination of Darunavir and Ritonavir as anti-HIV nanosuspension. J Mol Liq. 2019;293:111469. https:\/\/doi.org\/10.1016\/j.molliq.2019.111469.","DOI":"10.1016\/j.molliq.2019.111469"},{"issue":"5","key":"1386_CR4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jsps.2019.04.005","volume":"27","author":"B De Esp\u00edndola","year":"2019","unstructured":"De Esp\u00edndola B, Beringhs AO, Sonaglio D, Stulzer HK, Silva MAS, Ferraz HG, et al. Liquisolid pellets: a pharmaceutical technology strategy to improve the dissolution rate of Ritonavir. Saudi Pharm J. 2019;27(5):702\u201312. https:\/\/doi.org\/10.1016\/j.jsps.2019.04.005.","journal-title":"Saudi Pharm J"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jddst.2017.12.014","volume":"44","author":"S Kumar","year":"2018","unstructured":"Kumar S, Narayan R, Ahammed V, Nayak Y, Naha A, Nayak UY. Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting. J Drug Delivery Sci Technol. 2018;44:181\u20139. https:\/\/doi.org\/10.1016\/j.jddst.2017.12.014.","journal-title":"J Drug Delivery Sci Technol"},{"key":"1386_CR6","unstructured":"EMA. Norvir [Internet]. Eur Med Agency. 2018 [cited 2023 Jul 2]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/norvir."},{"key":"1386_CR7","doi-asserted-by":"publisher","unstructured":"Reyskens KMSE, Fisher T-L, Schisler JC, O'Connor WG, Rogers AB, Willis MS, et al. Cardio-metabolic effects of HIV Protease inhibitors (Lopinavir\/Ritonavir). PLoS ONE. 2013;8(9):e73347. https:\/\/doi.org\/10.1371\/journal.pone.0073347.","DOI":"10.1371\/journal.pone.0073347"},{"issue":"1","key":"1386_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.283.1.74","volume":"283","author":"MS Sulkowski","year":"2000","unstructured":"Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74. https:\/\/doi.org\/10.1001\/jama.283.1.74.","journal-title":"JAMA"},{"issue":"5","key":"1386_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/01913123.2014.914114","volume":"38","author":"C-C Kuang","year":"2014","unstructured":"Kuang C-C, Wang Y, Hu P-C, Gao F-F, Bu L, Wen X-M, et al. Ritonavir-induced hepatotoxicity and ultrastructural changes of hepatocytes. Ultrastruct Pathol. 2014;38(5):329\u201334. https:\/\/doi.org\/10.3109\/01913123.2014.914114.","journal-title":"Ultrastruct Pathol"},{"issue":"7","key":"1386_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/01.cir.100.7.700","volume":"100","author":"D P\u00e9riard","year":"1999","unstructured":"P\u00e9riard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study Circulation. 1999;100(7):700\u20135. https:\/\/doi.org\/10.1161\/01.cir.100.7.700.","journal-title":"The Swiss HIV Cohort Study Circulation"},{"issue":"1","key":"1386_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00002030-200001070-00006","volume":"14","author":"JQ Purnell","year":"2000","unstructured":"Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. Effect of Ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14(1):51\u20137. https:\/\/doi.org\/10.1097\/00002030-200001070-00006.","journal-title":"AIDS"},{"issue":"Suppl 2","key":"1386_CR12","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1086\/381444","volume":"38","author":"MS Sulkowski","year":"2004","unstructured":"Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S90-97. https:\/\/doi.org\/10.1086\/381444.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1386_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/17425247.2018.1503249","volume":"15","author":"RS Managuli","year":"2018","unstructured":"Managuli RS, Raut SY, Reddy MS, Mutalik S. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs. Expert Opin Drug Delivery. 2018;15(8):787\u2013804. https:\/\/doi.org\/10.1080\/17425247.2018.1503249.","journal-title":"Expert Opin Drug Delivery"},{"key":"1386_CR14","doi-asserted-by":"publisher","unstructured":"Darwis Y, Ali Khan A, Mudassir J, Mohtar N. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. IJN. 2013;2733. https:\/\/doi.org\/10.2147\/IJN.S41521.","DOI":"10.2147\/IJN.S41521"},{"issue":"3","key":"1386_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/BF00813500","volume":"18","author":"OJ Cohen","year":"1997","unstructured":"Cohen OJ, Pantaleo G, Lam GK, Fauci AS. Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Springer Semin Immunopathol. 1997;18(3):305\u201322. https:\/\/doi.org\/10.1007\/BF00813500.","journal-title":"Springer Semin Immunopathol"},{"key":"1386_CR16","doi-asserted-by":"publisher","unstructured":"Singh I, Swami R, Khan W, Sistla R. Delivery systems for lymphatic targeting. Focal Contr Drug Del. 2014;429\u201358. https:\/\/doi.org\/10.1007\/978-1-4614-9434-8_20.","DOI":"10.1007\/978-1-4614-9434-8_20"},{"key":"1386_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0076-6879(05)91019-7","volume":"391","author":"A D\u00e9sormeaux","year":"2005","unstructured":"D\u00e9sormeaux A, Bergeron MG. Lymphoid tissue targeting of anti-HIV drugs using liposomes. Methods Enzymol. 2005;391:330\u201351. https:\/\/doi.org\/10.1016\/S0076-6879(05)91019-7.","journal-title":"Methods Enzymol"},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/351693","volume":"2014","author":"A Mishra","year":"2014","unstructured":"Mishra A, Vuddanda PR, Singh S. Intestinal lymphatic delivery of Praziquantel by solid lipid nanoparticles: formulation design, in vitro and in vivo studies. J Nanotechnol. 2014;2014:1\u201312. https:\/\/doi.org\/10.1155\/2014\/351693.","journal-title":"J Nanotechnol"},{"issue":"1","key":"1386_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0169-409X(96)00494-2","volume":"25","author":"AJ Humberstone","year":"1997","unstructured":"Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev. 1997;25(1):103\u201328. https:\/\/doi.org\/10.1016\/S0169-409X(96)00494-2.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1386_CR20","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1007\/s13346-021-01014-4","volume":"12","author":"VC Gurumukhi","year":"2022","unstructured":"Gurumukhi VC, Bari SB. Quality by design (QbD)\u2013based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies. Drug Deliv and Transl Res. 2022;12(5):1230\u201352. https:\/\/doi.org\/10.1007\/s13346-021-01014-4.","journal-title":"Drug Deliv and Transl Res"},{"key":"1386_CR21","doi-asserted-by":"publisher","unstructured":"Patel P, Patel M. Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: In vitro, cell line and in vivo evaluation. Eur J Pharm Sci. 2021;159:105715. https:\/\/doi.org\/10.1016\/j.ejps.2021.105715.","DOI":"10.1016\/j.ejps.2021.105715"},{"key":"1386_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-01083-5","author":"VC Gurumukhi","year":"2021","unstructured":"Gurumukhi VC, Bari SB. Development of ritonavir-loaded nanostructured lipid carriers employing quality by design (QbD) as a tool: characterizations, permeability, and bioavailability studies. Drug Deliv Transl Res. 2021. https:\/\/doi.org\/10.1007\/s13346-021-01083-5.","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"1386_CR23","first-page":"1","volume":"2012","author":"CA Walimbe","year":"2012","unstructured":"Walimbe CA, More SS, Walawalkar RU, Shah RR, Ghodke D. Optimisation of nanostructured lipid carriers of ritonavir. Inventi Rapid: NDDS. 2012;2012(4):1\u20138.","journal-title":"Inventi Rapid: NDDS"},{"issue":"8","key":"1386_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/jphp.12737","volume":"69","author":"F Javan","year":"2017","unstructured":"Javan F, Vatanara A, Azadmanesh K, Nabi-Meibodi M, Shakouri M. Encapsulation of Ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles. J Pharm Pharmacol. 2017;69(8):1002\u20139. https:\/\/doi.org\/10.1111\/jphp.12737.","journal-title":"J Pharm Pharmacol"},{"key":"1386_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.lfs.2017.06.022","volume":"183","author":"V Ahammed","year":"2017","unstructured":"Ahammed V, Narayan R, Paul J, Nayak Y, Roy B, Shavi GV, et al. Development and in vivo evaluation of functionalized ritonavir proliposomes for lymphatic targeting. Life Sci. 2017;183:11\u201320. https:\/\/doi.org\/10.1016\/j.lfs.2017.06.022.","journal-title":"Life Sci"},{"key":"1386_CR26","doi-asserted-by":"publisher","unstructured":"Jitta SR, Bhaskaran NA, Salwa, Kumar L. Anti-oxidant containing nanostructured lipid carriers of Ritonavir: development, optimization, and in vitro and in vivo evaluations. AAPS PharmSciTech. 2022;23(4):88. https:\/\/doi.org\/10.1208\/s12249-022-02240-w.","DOI":"10.1208\/s12249-022-02240-w"},{"issue":"3","key":"1386_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/02726351.2020.1750515","volume":"39","author":"S Shrivastava","year":"2021","unstructured":"Shrivastava S, Gidwani B, Kaur CD. Development of mebendazole loaded nanostructured lipid carriers for lymphatic targeting: optimization, characterization, in-vitro and in-vivo evaluation. Parti Sci Technol. 2021;39(3):380\u201390. https:\/\/doi.org\/10.1080\/02726351.2020.1750515.","journal-title":"Parti Sci Technol"},{"issue":"7","key":"1386_CR28","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.3109\/10717544.2015.1037969","volume":"23","author":"MR Bhalekar","year":"2016","unstructured":"Bhalekar MR, Upadhaya PG, Madgulkar AR, Kshirsagar SJ, Dube A, Bartakke US. In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of Darunavir. Drug Delivery. 2016;23(7):2581\u20136. https:\/\/doi.org\/10.3109\/10717544.2015.1037969.","journal-title":"Drug Delivery"},{"issue":"6","key":"1386_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1468-1293.2005.00328.x","volume":"6","author":"SD Shafran","year":"2005","unstructured":"Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005;6(6):421\u20135. https:\/\/doi.org\/10.1111\/j.1468-1293.2005.00328.x.","journal-title":"HIV Med"},{"key":"1386_CR30","doi-asserted-by":"publisher","unstructured":"Onabajo OO, Lewis MG, Mattapallil JJ. GALT CD4+PD-1hi T follicular helper (Tfh) cells repopulate after antiretroviral therapy. Cell Immunolo. 2021;366:104396. https:\/\/doi.org\/10.1016\/j.cellimm.2021.104396.","DOI":"10.1016\/j.cellimm.2021.104396"},{"key":"1386_CR31","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jconrel.2020.10.036","volume":"329","author":"C Qin","year":"2021","unstructured":"Qin C, Chu Y, Feng W, Fromont C, He S, Ali J, et al. Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach. J Controlled Release. 2021;329:1077\u201389. https:\/\/doi.org\/10.1016\/j.jconrel.2020.10.036.","journal-title":"J Controlled Release"},{"issue":"4","key":"1386_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/cpt.2186","volume":"109","author":"EMB Scholz","year":"2021","unstructured":"Scholz EMB, Kashuba ADM. The lymph node reservoir: physiology, HIV infection, and Antiretroviral therapy. Clin Pharmacol Ther. 2021;109(4):918\u201327. https:\/\/doi.org\/10.1002\/cpt.2186.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1386_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ejps.2004.12.006","volume":"24","author":"A Dahan","year":"2005","unstructured":"Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci. 2005;24(4):381\u20138. https:\/\/doi.org\/10.1016\/j.ejps.2004.12.006.","journal-title":"Eur J Pharm Sci"},{"key":"1386_CR34","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.2147\/IJN.S214883","volume":"14","author":"H Liao","year":"2019","unstructured":"Liao H, Gao Y, Lian C, Zhang Y, Wang B, Yang Y, et al. Oral absorption and lymphatic transport of baicalein following drug\u2013phospholipid complex incorporation in self-microemulsifying drug delivery systems. IJN. 2019;14:7291\u2013306. https:\/\/doi.org\/10.2147\/IJN.S214883.","journal-title":"IJN"},{"issue":"3","key":"1386_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/pharmaceutics10030147","volume":"10","author":"J Qiao","year":"2018","unstructured":"Qiao J, Ji D, Sun S, Zhang G, Liu X, Sun B, et al. Oral bioavailability and lymphatic transport of pueraria flavone-loaded self-emulsifying drug-delivery systems containing sodium taurocholate in rats. Pharmaceutics. 2018;10(3):147. https:\/\/doi.org\/10.3390\/pharmaceutics10030147.","journal-title":"Pharmaceutics"},{"key":"1386_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.colsurfb.2018.11.057","volume":"175","author":"J Desai","year":"2019","unstructured":"Desai J, Thakkar H. Enhanced oral bioavailability and brain uptake of Darunavir using lipid nanoemulsion formulation. Colloids Surf B Biointerfaces. 2019;175:143\u20139. https:\/\/doi.org\/10.1016\/j.colsurfb.2018.11.057.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"11","key":"1386_CR37","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1211\/0022357011777972","volume":"53","author":"PB Nielsen","year":"2010","unstructured":"Nielsen PB, M\u00fcllertz A, Norling T, Kristensen HG. Comparison of the lymphatic transport of a lipophilic drug from vehicles containing \u03b1-tocopherol and\/or triglycerides in rats. J Pharm Pharmacol. 2010;53(11):1439\u201345. https:\/\/doi.org\/10.1211\/0022357011777972.","journal-title":"J Pharm Pharmacol"},{"key":"1386_CR38","doi-asserted-by":"publisher","unstructured":"Shete H, Chatterjee S, De A, Patravale V. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm. 2013;454(1):584\u201392. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.03.036.","DOI":"10.1016\/j.ijpharm.2013.03.036"},{"issue":"2","key":"1386_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1055\/s-2003-39949","volume":"23","author":"MS Sulkowski","year":"2003","unstructured":"Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis. 2003;23(2):183\u201394. https:\/\/doi.org\/10.1055\/s-2003-39949.","journal-title":"Semin Liver Dis"},{"key":"1386_CR40","doi-asserted-by":"publisher","unstructured":"Anghel L, Baroiu L, Beznea A, Grigore G. The therapeutic relevance of vitamin E. Revista de Chimie. 2019;70:3711\u20133. https:\/\/doi.org\/10.37358\/RC.19.10.7630.","DOI":"10.37358\/RC.19.10.7630"},{"issue":"1","key":"1386_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-2334-7-63","volume":"7","author":"SM Graham","year":"2007","unstructured":"Graham SM, Baeten JM, Richardson BA, Bankson DD, Lavreys L, Ndinya-Achola JO, et al. Higher pre-infection vitamin E levels are associated with higher mortality in HIV-1-infected Kenyan women: a prospective study. BMC Infec Dis. 2007;7(1):63. https:\/\/doi.org\/10.1186\/1471-2334-7-63.","journal-title":"BMC Infec Dis"},{"issue":"11","key":"1386_CR42","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1111\/jocd.13346","volume":"19","author":"M Ijaz","year":"2020","unstructured":"Ijaz M, Akhtar N. Fatty acids based \u03b1-Tocopherol loaded nanostructured lipid carrier gel: in vitro and in vivo evaluation for moisturizing and anti-aging effects. J Cosmet Dermatol. 2020;19(11):3067\u201376. https:\/\/doi.org\/10.1111\/jocd.13346.","journal-title":"J Cosmet Dermatol"},{"issue":"1\u20132","key":"1386_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ijpharm.2018.09.009","volume":"551","author":"C Caddeo","year":"2018","unstructured":"Caddeo C, Manca ML, Peris JE, Usach I, Diez-Sales O, Matos M, et al. Tocopherol-loaded transfersomes: in vitro antioxidant activity and efficacy in skin regeneration. Int J Pharm. 2018;551(1\u20132):34\u201341. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.09.009.","journal-title":"Int J Pharm"},{"key":"1386_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1472-6882-14-111","volume":"14","author":"S Palipoch","year":"2014","unstructured":"Palipoch S, Punsawad C, Koomhin P, Suwannalert P. Hepatoprotective effect of curcumin and alpha-tocopherol against cisplatin-induced oxidative stress. BMC Complement Altern Med. 2014;14:111. https:\/\/doi.org\/10.1186\/1472-6882-14-111.","journal-title":"BMC Complement Altern Med"},{"issue":"7","key":"1386_CR45","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/00002030-199207000-00013","volume":"6","author":"RS Beach","year":"1992","unstructured":"Beach RS, Mantero-Atienza E, Shor-Posner G, Javier JJ, Szapocznik J, Morgan R, et al. Specific nutrient abnormalities in asymptomatic HIV-1 infection. AIDS. 1992;6(7):701\u20138. https:\/\/doi.org\/10.1097\/00002030-199207000-00013.","journal-title":"AIDS"},{"issue":"5","key":"1386_CR46","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/00002030-199705000-00009","volume":"11","author":"AM Tang","year":"1997","unstructured":"Tang AM, Graham NM, Semba RD, Saah AJ. Association between serum vitamin A and E levels and HIV-1 disease progression. AIDS. 1997;11(5):613\u201320. https:\/\/doi.org\/10.1097\/00002030-199705000-00009.","journal-title":"AIDS"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01386-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01386-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01386-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T17:11:09Z","timestamp":1703265069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01386-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01386-9","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"type":"print","value":"2190-393X"},{"type":"electronic","value":"2190-3948"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"26 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were conducted with prior approval from the Institutional animal ethical committee (approval No. IAEC\/KMC\/51\/2018 and IAEC\/KMC\/72\/2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}